STX — Shield Therapeutics Balance Sheet
0.000.00%
- £24.48m
- £36.35m
- £13.09m
Annual balance sheet for Shield Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 4.14 | 2.94 | 16.3 | 3.4 | 13.9 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.15 | 0.656 | 4.73 | 4.51 | 11.2 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 6.39 | 5.23 | 23.3 | 12.2 | 31.3 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.026 | 0.032 | 0.41 | 0.238 | 0.673 |
Net Intangible Assets | |||||
Total Assets | 36.3 | 32.5 | 59.9 | 26.6 | 48.8 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.17 | 2.25 | 4.56 | 12.8 | 13.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 4.17 | 2.25 | 4.56 | 20.1 | 33.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 32.1 | 30.3 | 55.4 | 6.54 | 15 |
Total Liabilities & Shareholders' Equity | 36.3 | 32.5 | 59.9 | 26.6 | 48.8 |
Total Common Shares Outstanding |